ArticleEndocrinology, diabetes & metabolism2026
Reevaluating the Need for Routine IGF-1 Screening in Poorly Controlled Type 2 Diabetes Mellitus.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcromegaly is commonly associated with diabetes mellitus (DM), and its prevalence may be higher among individuals with type 2 DM than in the general population. This study aimed to assess the frequency of acromegaly in patients with poorly controlled type 2 DM.
methodsThis cross-sectional study included 504 patients (mean age: 57.7 ± 10.8 years) with uncontrolled type 2 DM (HbA1c > 8%) despite at least 1 year of insulin treatment (insulin alone or oral anti-diabetic drugs together with insulin). Serum insulin-like growth factor 1 (IGF-1) levels were measured for screening. In patients with elevated IGF-1, growth hormone (GH) levels were assessed by oral glucose tolerance test (OGTT). Pituitary magnetic resonance imaging (MRI) was performed in cases with persistently elevated IGF-1 and inadequate GH suppression or discordant post-glucose GH levels.
resultsThe median duration of DM was 9 (3-15) years, and the mean HbA1c was 11.12% ± 2.30%. Elevated serum IGF-1 levels were found in 2 of the 504 patients (0.39%). Both underwent OGTT for GH evaluation. One patient showed appropriate GH suppression, and the other demonstrated borderline GH suppression (a nadir GH of 0.88 ng/mL) with a 4 × 3 mm cystic pituitary lesion on MRI. However, given the absence of acromegalic clinical features and lack of biochemical confirmation, acromegaly was not diagnosed in either case.
conclusionRoutine IGF-1 screening in all patients with poorly controlled type 2 DM has limited diagnostic yield. IGF-1 testing should be reserved for patients exhibiting clinical features or phenotypic suspicion of acromegaly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.